Rothmund-Thomson syndrome type 1
roth-mund tom-son sin-drohm
Also known as: Poikiloderma Congenitale, RTS Type 1
At a Glance
What is Rothmund-Thomson syndrome type 1?
Rothmund-Thomson syndrome type 1 is a rare genetic disorder that primarily affects the skin, bones, and eyes. It is caused by mutations in the ANAPC1 gene, which disrupts normal cell cycle regulation. The condition usually begins in infancy with a characteristic rash that progresses to poikiloderma, a skin condition marked by changes in pigmentation, atrophy, and telangiectasia. Over time, individuals may develop skeletal abnormalities, cataracts, and an increased risk of certain cancers. Early symptoms include the distinctive rash and slow growth, while later symptoms can involve vision problems and bone issues. Early diagnosis is crucial to manage symptoms and monitor for complications like cancer. The condition can significantly impact family life due to the need for ongoing medical care and monitoring. Prognosis varies, but many individuals can lead relatively normal lives with appropriate management. Daily life may include regular dermatological care, orthopedic assessments, and eye examinations. Support from genetic counseling can help families understand the inheritance pattern and risks for future children. Despite the challenges, many affected individuals adapt well with support and medical care.
Medical Definition
Rothmund-Thomson syndrome type 1 is a genetic disorder characterized by poikiloderma, skeletal abnormalities, and an increased risk of malignancies. It is caused by biallelic mutations in the ANAPC1 gene, which encodes a scaffold subunit of the anaphase-promoting complex, leading to impaired cell cycle regulation. Histologically, the skin shows features of poikiloderma, including atrophy, telangiectasia, and pigmentary changes. The syndrome is classified into two types, with type 1 being associated with ANAPC1 mutations and lacking the RECQL4 mutations seen in type 2. Epidemiologically, it is an extremely rare condition with a prevalence of approximately 1 in 1,000,000. The disease course involves early onset in infancy and a lifelong risk of complications, particularly malignancies.
Rothmund-Thomson syndrome type 1 Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Poikiloderma manifests as a combination of skin atrophy, telangiectasia, and pigmentation changes, typically appearing in infancy. It is caused by mutations affecting skin cell repair and maintenance, leading to abnormal skin structure. Over time, the skin may become more fragile and prone to damage from environmental factors. This affects daily life by increasing the risk of skin infections and requiring protective measures such as sun avoidance and the use of emollients.
Sparse hair is characterized by thinning of scalp hair, eyebrows, and eyelashes, often noticeable from a young age. This occurs due to impaired hair follicle development and function, linked to genetic mutations. As the individual ages, hair may become progressively thinner and more brittle. This can impact self-esteem and social interactions, necessitating cosmetic solutions like wigs or hairpieces.
Short stature is a condition where an individual's height is significantly below average for their age and sex. It results from disruptions in growth hormone pathways and skeletal development due to genetic mutations. Growth velocity is typically reduced, leading to noticeable differences in height compared to peers over time. This can affect physical activities and social experiences, often requiring growth hormone therapy or orthopedic interventions.
Common
Cataracts involve clouding of the eye's lens, leading to vision impairment. They develop due to protein aggregation in the lens, often accelerated by genetic factors in Rothmund-Thomson syndrome. Vision may gradually worsen, affecting daily activities like reading and driving. Surgical removal of the cataract can restore vision, although regular monitoring is necessary.
Skeletal abnormalities can include radial ray defects, absent or malformed bones, and delayed bone age. These arise from disrupted bone development processes due to genetic mutations. Over time, these abnormalities can lead to functional impairments and increased fracture risk. Management may involve orthopedic surgery and physical therapy to improve mobility and function.
Gastrointestinal issues may present as chronic diarrhea, constipation, or malabsorption. These symptoms are due to abnormalities in the gastrointestinal tract's structure and function, influenced by genetic mutations. Over time, they can lead to nutritional deficiencies and growth delays. Dietary management and supplementation can help alleviate symptoms and support growth.
Less Common
Neutropenia is characterized by a low count of neutrophils, a type of white blood cell, leading to increased infection risk. It results from bone marrow dysfunction associated with genetic mutations. The condition may fluctuate over time, with periods of normal and low neutrophil counts. Regular monitoring and prompt treatment of infections are crucial to managing this symptom.
Dental anomalies can include delayed eruption, missing teeth, and enamel defects. These occur due to disruptions in dental development and mineralization processes. Over time, these anomalies can lead to functional and aesthetic concerns, impacting chewing and appearance. Regular dental care and orthodontic treatment can help manage these issues and improve oral health.
What Causes Rothmund-Thomson syndrome type 1?
Rothmund-Thomson syndrome type 1 is caused by mutations in the ANAPC1 gene, which is located on chromosome 2q24.3. The ANAPC1 gene encodes a scaffold subunit of the anaphase-promoting complex (APC/C), a crucial E3 ubiquitin ligase that regulates the cell cycle by targeting specific proteins for degradation. Mutations in ANAPC1 disrupt the structure of the APC/C, impairing its ability to ubiquitinate target proteins, leading to cell cycle arrest or apoptosis. This disruption causes accumulation of cell cycle regulators, resulting in impaired cell division and genomic instability. Dysfunction of the APC/C affects the integrity of the centrosome and mitotic spindle, leading to defects in chromosome segregation. Neighboring cells experience increased stress due to the accumulation of damaged cells, triggering compensatory proliferation and inflammation. Neuroinflammation may be exacerbated by the release of cytokines from stressed or dying cells, contributing to tissue damage. Degeneration of white matter and other structures occurs due to chronic inflammation and impaired cellular repair mechanisms. Symptoms appear in a specific pattern due to the differential vulnerability of tissues to genomic instability and inflammation. The variability in disease severity among patients is influenced by the type and location of the ANAPC1 mutations, as well as environmental and genetic modifiers. Some patients may experience more severe skin manifestations, while others have pronounced skeletal or hematological abnormalities. The presence of other genetic variants can modulate the clinical presentation, leading to a spectrum of phenotypes. Early diagnosis and intervention can help manage symptoms and improve quality of life. Understanding the molecular basis of Rothmund-Thomson syndrome type 1 is crucial for developing targeted therapies.
How is Rothmund-Thomson syndrome type 1 Diagnosed?
Typical age of diagnosis: Rothmund-Thomson syndrome type 1 is typically diagnosed in infancy or early childhood, often when characteristic skin changes such as poikiloderma appear. Diagnosis may be delayed if symptoms are mild or atypical, necessitating a high index of suspicion by clinicians. Early recognition is crucial for appropriate management and genetic counseling. Diagnosis involves a combination of clinical evaluation, imaging, laboratory tests, and genetic testing.
Clinicians look for characteristic skin changes such as poikiloderma, sparse hair, and nail abnormalities. A detailed family history is important to identify any hereditary patterns. Physical examination may reveal growth retardation and skeletal abnormalities. This step helps to differentiate Rothmund-Thomson syndrome from other genodermatoses.
X-rays are commonly used to assess skeletal abnormalities, such as radial ray defects. Specific abnormalities like osteopenia or absent thumbs can be visible. Imaging findings help confirm the diagnosis by correlating with clinical features. Differential diagnoses such as other skeletal dysplasias can be excluded based on imaging results.
Blood tests may be ordered to assess hematological abnormalities, such as neutropenia. Specific biomarkers like elevated inflammatory markers can be sought. Abnormal results may show cytopenias or other blood cell anomalies. These results guide further genetic testing and management decisions.
Genetic testing involves sequencing the ANAPC1 gene to identify biallelic mutations. Mutations such as nonsense or frameshift types are commonly found. Positive results confirm the diagnosis of Rothmund-Thomson syndrome type 1. Genetic results are crucial for family counseling and assessing recurrence risk.
Rothmund-Thomson syndrome type 1 Treatment Options
Topical corticosteroids are used to manage skin inflammation and poikiloderma. They work by reducing inflammation and modulating immune responses in the skin. Specific drugs like hydrocortisone or betamethasone may be used. Clinical evidence supports their efficacy in reducing skin symptoms, although they do not address systemic features. Long-term use can lead to skin thinning and other local side effects.
Occupational therapy focuses on improving fine motor skills and daily living activities. Techniques include exercises to enhance hand function and adaptive strategies for independence. Sessions are typically conducted weekly, with duration tailored to individual needs. Measurable outcomes include improved dexterity and functional independence. Long-term benefits include enhanced quality of life and reduced disability.
Surgery is indicated for significant skeletal deformities impacting function. The procedure involves realigning bones to correct deformities and improve function. Expected benefits include improved limb function and reduced pain. Surgical risks include infection, bleeding, and need for revision surgery. Post-operative care involves physical therapy and regular follow-up to monitor healing.
The care team typically includes dermatologists, geneticists, orthopedic surgeons, and psychologists. Interventions focus on managing skin symptoms, monitoring growth, and addressing psychosocial needs. Psychosocial support includes counseling and support groups for patients and families. Family education is provided on disease management and genetic implications. Long-term monitoring involves regular assessments to manage complications and adjust treatment plans.
When to See a Doctor for Rothmund-Thomson syndrome type 1
- Severe skin blistering — this can indicate a serious complication requiring immediate medical attention.
- Unexplained high fever — may suggest an infection or systemic involvement that needs urgent evaluation.
- Sudden vision loss — could be a sign of retinal detachment or other ocular emergencies associated with the syndrome.
- Persistent joint pain — may indicate underlying skeletal abnormalities and should be assessed by a specialist.
- Delayed growth or development — important to address with a pediatrician to evaluate for potential interventions.
- Frequent infections — suggestive of possible immune system involvement, requiring further investigation.
- Mild skin rash — monitor for changes in size or severity, and consult a dermatologist if it worsens.
- Occasional fatigue — observe for patterns and ensure adequate rest, but seek advice if it becomes chronic.
Rothmund-Thomson syndrome type 1 — Frequently Asked Questions
Is this condition hereditary?
Rothmund-Thomson syndrome type 1 is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an individual with this condition are typically carriers, having one mutated gene and one normal gene. There is a 25% chance with each pregnancy for carrier parents to have an affected child. De novo mutations are not common in this condition. Genetic counseling is recommended for families to understand inheritance patterns and carrier testing.
What is the life expectancy for someone with this condition?
Life expectancy can vary based on the severity of symptoms and complications. Early onset with severe symptoms may lead to a reduced lifespan, particularly if complications like cancer arise. Regular monitoring and treatment can improve outcomes and quality of life. Mortality is often related to complications such as infections or malignancies. With appropriate care, individuals can have a relatively normal lifespan.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, genetic testing, and family history assessment. The time from first symptoms to diagnosis can vary, often taking months to years due to the rarity of the condition. Dermatologists, geneticists, and pediatricians are typically involved in the diagnostic process. Delays often occur due to the overlap of symptoms with other conditions. Genetic testing confirming mutations in the ANAPC1 gene finalizes the diagnosis.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy and targeted molecular treatments being explored. Novel approaches aim to address the genetic basis of the syndrome. ClinicalTrials.gov is a resource for finding current trials, and patients should discuss potential participation with their healthcare provider. It's important to ask about the risks and benefits of experimental treatments. New treatments may take several years to become widely available.
How does this condition affect daily life and activities?
Individuals may experience limitations in mobility and self-care due to skin and skeletal issues. Educational support is often necessary to accommodate learning challenges. Social interactions can be affected by visible symptoms, leading to emotional stress. Family members may face increased caregiving responsibilities. Supportive therapies and adaptive devices can significantly enhance quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.When Rothmund-Thomson syndrome is not: two new cases of Clericuzio-type poikiloderma with neutropenia.
Tadros S, Forde K, Syed S et al. · Clin Dysmorphol · 2021 · PMID: 32897901
- 2.Pregnancy in a patient with Rothmund-Thomson type 2 syndrome.
Bognoni L, Colombo EA, Priolo M et al. · Int J Gynaecol Obstet · 2021 · PMID: 33660851
- 3.Rothmund-Thomson syndrome type 1 caused by biallelic ANAPC1 gene mutations.
Zirn B, Bernbeck U, Alt K et al. · Skin Health Dis · 2021 · PMID: 35664819
- 4.Poikiloderma Congenitale.
Hafsi W, Badri T · Unknown Journal · 2026 · PMID: 30252379
- 5.Mutations in ANAPC1, Encoding a Scaffold Subunit of the Anaphase-Promoting Complex, Cause Rothmund-Thomson Syndrome Type 1.
Ajeawung NF, Nguyen TTM, Lu L et al. · Am J Hum Genet · 2019 · PMID: 31303264
- 6.Precocious puberty and anal stenosis in an African patient with Rothmund-Thomson syndrome.
Lorenzo C, Travessa AM, Ferreira AC et al. · Am J Med Genet A · 2023 · PMID: 36164748
- 7.Molecular insights into genodermatoses: Genetic findings from 43 patients.
Sama AD, Avci Durmusalioglu E, Isik E et al. · Arch Dermatol Res · 2025 · PMID: 40025372
- 8.Sensitivity of RECQL4-deficient fibroblasts from Rothmund-Thomson syndrome patients to genotoxic agents.
Jin W, Liu H, Zhang Y et al. · Hum Genet · 2008 · PMID: 18504617
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-10